ProQR Therapeutics N.V. buy Chardan Capital
Start price
10.05.24
/
50%
€1.86
Target price
10.05.25
€2.32
Performance (%)
-14.52%
Price
21.06.24
€1.59
Summary
This prediction is currently active. The prediction for ProQR Therapeutics N.V. disappoints with a performance of -14.52%. This prediction currently runs until 10.05.25. The prediction end date can be changed by Chardan_Capital at any time. Chardan_Capital has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
ProQR Therapeutics N.V. | -5.357% | -5.357% |
iShares Core DAX® | 1.080% | -2.933% |
iShares Nasdaq 100 | 0.362% | 7.015% |
iShares Nikkei 225® | -1.155% | -1.155% |
iShares S&P 500 | 0.806% | 4.388% |
Comments by Chardan_Capital for this prediction
In the thread ProQR Therapeutics N.V. diskutieren
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.
Ratings data for PRQR provided by MarketBeat
Stopped prediction by Chardan_Capital for ProQR Therapeutics N.V.
ProQR Therapeutics N.V.
Start price
Target price
Perf. (%)
€1.27
08.11.23
08.11.23
€1.87
08.11.24
08.11.24
25.59%
21.06.24
21.06.24